Literature DB >> 8698376

Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

G T Layton1, S J Harris, J Myhan, D West, F Gotch, M Hill-Perkins, J S Cole, N Meyers, S Woodrow, T J French, S E Adams, A J Kingsman.   

Abstract

The induction of cytotoxic T-lymphocyte (CTL) responses to viral proteins is thought to be an essential component of protective immunity against viral infections. Methods for generating such responses in a reproducible manner would be of great value in vaccine development. We demonstrate here that the recombinant antigen-presentation system based on the yeast transposon (Ty) particle-forming p1 protein is a potent means of inducing CTL responses to a variety of viral CTL epitopes, including influenza virus nucleoprotein (two epitopes), Sendai virus and vesicular stomatitis virus nucleoproteins, and the V3 loop of human immunodeficiency virus type-1 (HIV-1) gp120. CTL were primed by hybrid Ty-virus-like particles (VLP) carrying the minimal epitope or as much as 19,000 MW of protein. Ty-VLP carrying two different epitopes (dual-epitope Ty-VLP) were capable of priming CTL responses in two different strains of mice or against two epitopes in the same individual. Furthermore, co-administration of a mixture of two different Ty-VLP carrying single epitopes could induce responses to both epitopes in the same individual. Ty-VLP appear to represent a reproducible and flexible system for inducing CTL responses in mice, and warrant further evaluation in primates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698376      PMCID: PMC1384270          DOI: 10.1046/j.1365-2567.1996.464539.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles.

Authors:  F Zhou; B T Rouse; L Huang
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

2.  Peptide selection by class I molecules of the major histocompatibility complex.

Authors:  T Elliott; M Smith; P Driscoll; A McMichael
Journal:  Curr Biol       Date:  1993-12-01       Impact factor: 10.834

3.  Immunodominance: intramolecular competition between T cell epitopes.

Authors:  D L Perkins; G Berriz; T Kamradt; J A Smith; M L Gefter
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

Review 4.  Molecular anatomy of viral persistence.

Authors:  M B Oldstone
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 5.  Polyvalent recombinant antigens: a new vaccine strategy.

Authors:  S M Kingsman; A J Kingsman
Journal:  Vaccine       Date:  1988-08       Impact factor: 3.641

6.  Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

Authors:  J Y Wu; B H Gardner; C I Murphy; J R Seals; C R Kensil; J Recchia; G A Beltz; G W Newman; M J Newman
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

7.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.

Authors:  M Kovacsovics-Bankowski; K Clark; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  H-2Kd-restricted antigenic peptides share a simple binding motif.

Authors:  P Romero; G Corradin; I F Luescher; J L Maryanski
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

9.  Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells.

Authors:  A Aggarwal; S Kumar; R Jaffe; D Hone; M Gross; J Sadoff
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

10.  Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.

Authors:  A Townsend; J Bastin; K Gould; G Brownlee; M Andrew; B Coupar; D Boyle; S Chan; G Smith
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  7 in total

1.  Virus-like particles as vaccine adjuvants.

Authors:  S C Gilbert
Journal:  Mol Biotechnol       Date:  2001-10       Impact factor: 2.695

2.  Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes.

Authors:  Rafael Cubas; Sheng Zhang; Sunkuk Kwon; Eva M Sevick-Muraca; Min Li; Changyi Chen; Qizhi Yao
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

Review 3.  Immunity to liver stage malaria: considerations for vaccine design.

Authors:  Andrew W Taylor-Robinson
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.

Authors:  Somayeh Pouyanfard; Taravat Bamdad; Hamidreza Hashemi; Mojgan Bandehpour; Bahram Kazemi
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

Review 5.  Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.

Authors:  Marine L B Hillaire; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Biomed Biotechnol       Date:  2011-10-05

6.  Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice.

Authors:  Atefeh Razazan; Jessica Nicastro; Roderick Slavcev; Nastaran Barati; Atefeh Arab; Fatemeh Mosaffa; Mahmoud Reza Jaafari; Javad Behravan
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

7.  Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.

Authors:  Ekta Mukhopadhyay; Florian Brod; Philip Angell-Manning; Nicola Green; Richard D Tarrant; Frank J Detmers; Emma J Bolam; Ioana N Baleanu; Mark Hobson; Gary Whale; Susan J Morris; Rebecca Ashfield; Sarah C Gilbert; Jing Jin; Simon J Draper; Sarah P Moyle; Eleanor L Berrie; Adrian V S Hill
Journal:  Biotechnol Bioeng       Date:  2022-07-22       Impact factor: 4.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.